<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>9(6)</volume><submitter>Wu Y</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Accumulating evidence suggests that hypoglycaemic agents influence lung cancer risk in patients with diabetes. It remains to be fully elucidated whether conventional hypoglycaemic agents (metformin, sulfonylureas, thiazolidinediones [TZDs] or insulin) affect lung cancer incidence in patients with diabetes.&lt;h4>Methods&lt;/h4>We performed a meta-analysis using EMBASE, MEDLINE and Web of Science to search randomised controlled trials (RCTs), cohort studies, and case-control studies published up to October 2013 that assessed the effects of metformin, sulfonylurea, TZDs or insulin on lung cancer risk in subjects with diabetes. Fixed and random effects meta-analysis models were used, and the effect size was expressed as a summary odds ratio (OR) with 95% confidence intervals (CI)</pubmed_abstract><journal>PloS one</journal><pagination>e99577</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4055722</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.</pubmed_title><pmcid>PMC4055722</pmcid><pubmed_authors>Shi XF</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Liu HB</pubmed_authors><pubmed_authors>Song Y</pubmed_authors></additional><is_claimable>false</is_claimable><name>Conventional hypoglycaemic agents and the risk of lung cancer in patients with diabetes: a meta-analysis.</name><description>&lt;h4>Background&lt;/h4>Accumulating evidence suggests that hypoglycaemic agents influence lung cancer risk in patients with diabetes. It remains to be fully elucidated whether conventional hypoglycaemic agents (metformin, sulfonylureas, thiazolidinediones [TZDs] or insulin) affect lung cancer incidence in patients with diabetes.&lt;h4>Methods&lt;/h4>We performed a meta-analysis using EMBASE, MEDLINE and Web of Science to search randomised controlled trials (RCTs), cohort studies, and case-control studies published up to October 2013 that assessed the effects of metformin, sulfonylurea, TZDs or insulin on lung cancer risk in subjects with diabetes. Fixed and random effects meta-analysis models were used, and the effect size was expressed as a summary odds ratio (OR) with 95% confidence intervals (CI)</description><dates><release>2014-01-01T00:00:00Z</release><publication>2014</publication><modification>2025-04-19T02:39:20.508Z</modification><creation>2019-03-26T23:26:12Z</creation></dates><accession>S-EPMC4055722</accession><cross_references><pubmed>24924771</pubmed><doi>10.1371/journal.pone.0099577</doi></cross_references></HashMap>